Reference is made to the stock exchange announcement published on30 November 2023 byExact Therapeutics AS ("Exact-Tx" or the "Company") regarding a completed private placement (the "Private Placement") of new shares in the Company. The issuance of 2,083,333 new shares has now been registered with theNorwegian Register ofBusiness Enterprises (the "NRBE") (Nw: Foretaksregisteret). Following registration of the share capital increase, the Company's share capital isNOK 128,322.208 divided into 32,050,552 shares, each with a par value ofNOK 0.004 . This information is subject to the disclosure requirements pursuant to Euronext Growth Oslo Rule Book - Part II, section 3.11.5 (3). For more information, please contact: CEO Per Walday, per.walday@exact-tx.com CFOJohn M. Edminson , john.edminson@exact-tx.com About EXACT-Tx: EXACT-Tx is a Norwegian clinical-stage precision medicine company developing a technology platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted drug enhancement - with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy) and brain diseases. www.exact-tx.com
Click here for more information
© Oslo Bors ASA, source